Efti Trial Shows 81% Sarcoma Disease-Free Survival

Interim EFTISARC-NEO data from an investigator-led Phase II trial report 12-month disease-free survival in resectable soft tissue sarcoma.

Updated on Nov. 11, 2026 in Cancer

Efti Trial Shows 81% Sarcoma Disease-Free Survival

Immutep Limited released an abstract reporting interim disease-free survival data from EFTISARC-NEO, a Phase II trial of eftilagimod alfa plus KEYTRUDA and radiotherapy given before surgery for resectable soft tissue sarcoma. Investigators concluded the preliminary long-term outcomes warrant registrational trials.

Why it matters

Soft tissue sarcoma treatment options before surgery are limited, so interim survival figures from a neoadjuvant combination regimen are closely watched by oncologists. Investigators say the results support moving toward larger, registrational studies.

The 12-month disease-free survival rate of 81.1% was measured in 38 evaluable patients with a median follow-up of 19.1 months, a small interim sample from a Phase II trial. Whether tumour hyalinisation/fibrosis predicts better disease-free survival remains unconfirmed pending longer follow-up.

The players

Immutep Limited

An Australian biotechnology company, headquartered in Sydney, developing immunotherapies including eftilagimod alfa (efti).

Maria Skłodowska-Curie National Research Institute of Oncology

A leading Polish cancer research and treatment institution based in Warsaw that leads the EFTISARC-NEO trial.

The details

EFTISARC-NEO is an investigator-initiated trial led by the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw, Poland, and is primarily funded by a Polish Medical Research Agency grant, with Immutep supplying efti. The trial previously met its primary endpoint, with median tumour hyalinisation/fibrosis of 51.5%, and no differences in disease-free survival were seen across tumour grade, stage or histological subtype.

Timeline

  1. October 2025: EFTISARC-NEO met its primary endpoint.

  2. April 2026: The U.S. FDA granted Orphan Drug Designation to efti for soft tissue sarcoma.

  3. 30 April 2026: Data cut-off for the survival analysis.

  4. November 2026: Further analyses to be presented in a poster discussion session on 19 November 2026.

Health Landscape

The EFTISARC-NEO result extends the EFTISARC research program's push to add immunotherapy to radiotherapy before surgery in soft tissue sarcoma, a disease with few neoadjuvant options. Its outcomes will be compared against standard pre-operative radiotherapy, which historically produced hyalinisation in only about 15% of tumours.

For patients with resectable soft tissue sarcoma, a pre-surgery immunotherapy plus radiotherapy approach is not yet available outside trials, so these results do not change current care. Patients and clinicians should follow ongoing registrational studies for any future access.

The takeaway

Early survival signals in this trial are encouraging, but the sample of 38 patients is small and follow-up is still short. Readers should treat the figures as preliminary until larger, longer-term results are published.

What happens next

Further analyses from EFTISARC-NEO will be presented in a poster discussion session on 19 November 2026 at the CTOS 2026 Annual Meeting in Seoul, South Korea, held 18-21 November 2026.

Further reading

For more on the disease, see our Cancer coverage.